Mylan sees opportunity in rival Teva's weakness - MarketWatch
Teva Pharmaceutical's Stock Tumbles on Outlook - WSJ
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
Teva's Earnings and Outlook Miss Estimates. Currency Moves Are to Blame. | Barron's
Teva's CEO Kåre Schultz to retire at year end, succeeded by Richard Francis
Teva's Battered Stock Looks Extremely Cheap | Barron's
Teva Stock Soars After Reaching $4.25 Billion Opioid Settlement | Barron's
Warren Buffett Stocks Fall: Teva Pharmaceutical Up 1.8%; StoneCo Off 3.7% - TheStreet
Teva - Updates, News, Events, Signals & Triggers
Teva earnings preview: Opioid suits are 'key' - MarketWatch
Teva shares hit 19-year low after opioid settlement, analyst downgrades | Fierce Pharma
Bandita tó Nyugtató teva fda warning Furcsa redőny meghallgatás
Teva Stock Sees Another Big Buy From Chairman Sol Barer | Barron's
Teva Pharmaceutical Names Richard Francis as CEO, President - WSJ
What To Do After TEVA Stock Falls Below $10 Again (NYSE:TEVA) | Seeking Alpha
Teva to acquire Mexico's Rimsa for $2.3 billion - MarketWatch
Teva Pharmaceuticals - Wikiwand
Drug Stock Due for Another Climb on the Charts
TEVA -- Is Its Stock Price A Worthy Investment? Learn More.
Investors wary of Teva-Mylan merger - MarketWatch
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
Teva Tries to Put an End to the Opioid Wars - WSJ
Teva Stock Falls Because 2019 Will Be a 'Trough Year' | Barron's
Why Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is Coming Back
Teva shares surge on corporate shake-up - MarketWatch
